UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~January 2925, ~~2024~~2025

~~MYCOTOPIA THERAPIES~~AIBOTICS, INC.

(Exact name of registrant as specified in its charter)

______________________________________________

Nevada		000-56022		87-0645794
(State of Incorporation)		(Commission File Number)		(IRS Employer ID No.)

100 SE 2nd St, Suite 2000

Miami, Florida 33131

(Address of Principal Executive Offices)

(954) 233-3511

(Registrant's Telephone Number including Area Code)

____________________________________________

(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ~~[ ]~~¨

SECTION 1. REGISTRANT’S BUSINESS AND OPERATIONS

Item 1.01 Entry into a Material Definitive Agreement.

On ~~July~~January 2925, ~~2024~~2025, ~~the~~Aibotics ~~Mycotopia~~ Inc. (the “Company”) entered into ana ~~Exchange~~software ~~Agreement~~development ~~with~~agreement ~~Ehave~~(the ~~Inc.,~~“Agreement”) ~~its~~with ~~largest~~GMF ~~shareholder~~Ventures, ~~whereby~~LLC ~~Ehave~~(“GMF”) ~~exchanged 9,793,754 shares of Company common stock~~ for 1the ~~share~~development of ~~the~~iOS ~~newly~~and ~~designated~~Android ~~Series~~based Aapplications ~~Super~~for ~~Voting~~its ~~Stock~~Philbot ~~(“Series~~massage ~~A Preferred”)~~robot.

The ~~holder~~Company ofwill ~~the~~pay ~~Series A~~GMF ~~Preferred~~Ventures isa ~~entitled~~total ~~to cast that number~~ of ~~votes~~$165,000 ~~on all matters presented~~ for ~~stockholder~~services ~~vote~~under to the ~~stockholders~~contract. ofThe ~~the~~first ~~Corporation~~payment ~~that~~pursuant ~~when~~to ~~taking into account~~ the ~~votes~~Agreement ~~entitled~~has tobeen bemade ~~cast~~via by the ~~Series~~issuance Aof ~~Preferred~~500,000 ~~stockholder~~shares ~~is equal to seventy-five percent (75%)~~ of the ~~total~~Company’s ~~shares~~common ~~authorized~~stock to ~~vote~~Steve onFleurimont ~~such~~issued ~~matter(s)~~pursuant ~~and~~to ~~such~~the ~~holder~~Company’s ~~shall~~Equity ~~vote~~Incentive ~~along~~Plan ~~with~~as ~~holders~~set offorth in the ~~Corporation~~Company’s ~~Common~~registration ~~Stock~~statement on ~~such~~Form ~~matters.~~S-8 ~~The~~filed ~~number~~with ~~of votes that~~ the ~~holder~~SEC ~~of the Series A Preferred shares shall be entitled to cast~~ on aSeptember ~~matter~~13, at2024. ~~any time shall be determined pursuant to the following formula:~~

X = 3 x Y where

X is the total number of votes that the holder of the Series A Preferred share is entitled to cast on any matter presented to stockholders of the Corporation, and

Y is the total number of authorized shares of the Corporation outstanding and authorized to vote on the matter.

Additionally, the Series A Preferred Stock is convertible into 9,793,754 shares of Company common stock at the option of the holder.

The description of the designation of the Series A Preferred stock and the Exchange Agreement contained herein are each qualified in their entirety by reference to the designation for the Series A Preferred and the Exchange Agreement attached hereto as exhibits.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 24, 2024, the Board of Directors of the Company approved the designation of the Series A Super Voting Stock, the Exchange Agreement with Ehave, Inc., and an amendment to the Company’s articles of incorporation increasing the number of authorized shares of common stock to 467,000,000 (Four Hundred Sixty-Seven Million). The designation of the Series A Preferred and the amendment increasing the authorized common stock were filed with the state of Nevada on August 8, 2024.

The description of the designation of the Series A Preferred stock contained herein is qualified in its entirety the by reference to the designation for the Series A Preferred attached hereto as an exhibit.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.		Description
3.1		Amendment to Articles of Incorporation Increasing Authorized
10.1		Software Development Agreement
3.2		Designation of Series A Super Voting Preferred Stock
10.1		Exchange Agreement with Ehave Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Mycotopia Therapies, Inc.
	Aibotics Inc.
	a Nevada corporation
Date: August 20, 2024	By: /s/Ben Kaplan
Date: March 21, 2025	By:	/s/Ben Kaplan
	Name: Ben Kaplan
	Name:	Ben Kaplan
	Title: Chief Executive Officer and Principal Accounting Officer
	Title:	Chief Executive Officer and Principal Accounting Officer

Filing Compare · AIBOTICS, INC.